JP2023052878A5 - - Google Patents

Download PDF

Info

Publication number
JP2023052878A5
JP2023052878A5 JP2023015070A JP2023015070A JP2023052878A5 JP 2023052878 A5 JP2023052878 A5 JP 2023052878A5 JP 2023015070 A JP2023015070 A JP 2023015070A JP 2023015070 A JP2023015070 A JP 2023015070A JP 2023052878 A5 JP2023052878 A5 JP 2023052878A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023015070A
Other languages
English (en)
Other versions
JP2023052878A (ja
Filing date
Publication date
Priority claimed from JP2020200158A external-priority patent/JP2021050218A/ja
Application filed filed Critical
Publication of JP2023052878A publication Critical patent/JP2023052878A/ja
Publication of JP2023052878A5 publication Critical patent/JP2023052878A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 本願明細書に記載された発明。
JP2023015070A 2015-01-26 2023-02-03 チロシンキナーゼ阻害剤を用いる組成物および方法 Pending JP2023052878A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107553P 2015-01-26 2015-01-26
US62/107,553 2015-01-26
US201562250052P 2015-11-03 2015-11-03
US62/250,052 2015-11-03
JP2020200158A JP2021050218A (ja) 2015-01-26 2020-12-02 チロシンキナーゼ阻害剤を用いる組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020200158A Division JP2021050218A (ja) 2015-01-26 2020-12-02 チロシンキナーゼ阻害剤を用いる組成物および方法

Publications (2)

Publication Number Publication Date
JP2023052878A JP2023052878A (ja) 2023-04-12
JP2023052878A5 true JP2023052878A5 (ja) 2023-10-02

Family

ID=56544226

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017539224A Active JP6854766B2 (ja) 2015-01-26 2016-01-26 チロシンキナーゼ阻害剤を用いる組成物および方法
JP2020200158A Pending JP2021050218A (ja) 2015-01-26 2020-12-02 チロシンキナーゼ阻害剤を用いる組成物および方法
JP2023015070A Pending JP2023052878A (ja) 2015-01-26 2023-02-03 チロシンキナーゼ阻害剤を用いる組成物および方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017539224A Active JP6854766B2 (ja) 2015-01-26 2016-01-26 チロシンキナーゼ阻害剤を用いる組成物および方法
JP2020200158A Pending JP2021050218A (ja) 2015-01-26 2020-12-02 チロシンキナーゼ阻害剤を用いる組成物および方法

Country Status (8)

Country Link
US (3) US10471059B2 (ja)
EP (1) EP3250192A4 (ja)
JP (3) JP6854766B2 (ja)
CN (2) CN113244399A (ja)
CA (1) CA2974958A1 (ja)
HK (1) HK1245678A1 (ja)
MX (2) MX2017009643A (ja)
WO (1) WO2016123086A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3049926A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN106943595A (zh) * 2017-03-30 2017-07-14 福州大学 Src/Abl抑制剂作为预防或治疗辐射损伤药物的应用
EP3823615A4 (en) * 2018-06-18 2022-04-06 Duke University COMPOSITIONS AND METHODS OF TREATMENT OF DISORDERS CHARACTERIZED BY ABERRANTE RAS/MAPK SIGNALING
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US20220117966A1 (en) * 2019-02-27 2022-04-21 Astrazeneca Ab Method of treating fibrosis
WO2021119525A1 (en) * 2019-12-11 2021-06-17 Tiaki Therapeutics Inc. Shp1 and shp2 inhibitors and their methods of use
EP4255436A4 (en) * 2020-12-07 2024-10-23 Hht Foundation Int Inc METHOD OF TREATMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA USING PAZOPANIB
WO2023127012A1 (ja) * 2021-12-27 2023-07-06 国立研究開発法人理化学研究所 動脈瘤の治療及び/又は予防のための医薬組成物、動脈瘤の診断補助方法、並びに動脈瘤治療薬の評価方法
WO2023175136A1 (en) * 2022-03-18 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of dasatinib and lovastatin for use in methods for the treatment of cardiac fibrosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355786B1 (en) * 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
CA2388343A1 (en) 1999-11-12 2001-05-17 Mark Steven Marshall Methods for inhibiting neurofibromatosis type 1 (nf1)
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2579519A1 (en) 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells
EP1901764A1 (en) * 2005-07-14 2008-03-26 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
US20070123539A1 (en) * 2005-10-20 2007-05-31 University Of South Florida Treatment of Restenosis and Stenosis with Dasatinib
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
CN103463621B (zh) * 2006-10-31 2016-01-06 托莱多大学 Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
EP2359813A1 (en) * 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
JP2016506417A (ja) * 2013-01-10 2016-03-03 プルモキネ、インコーポレイテッド キナーゼ阻害剤の治療指標
EP3019491A4 (en) * 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc KINASE INHIBITORS FOR THE TREATMENT OF DISEASE

Similar Documents

Publication Publication Date Title
JP2023105131A5 (ja)
JP2021151238A5 (ja)
JP2020007340A5 (ja)
JP2023085489A5 (ja)
JP2020040981A5 (ja)
JP2022068302A5 (ja)
JP2021048879A5 (ja)
JP2022028828A5 (ja)
JP2022025124A5 (ja)
JP2021185136A5 (ja)
JP2021100406A5 (ja)
JP2023052878A5 (ja)
JP2023022224A5 (ja)
JP2022185040A5 (ja)
JP2022122972A5 (ja)
JP2024026077A5 (ja)
JP2024016014A5 (ja)
JP2022060295A5 (ja)
JP2022064180A5 (ja)
JP2020079331A5 (ja)
JP2023116477A5 (ja)
JP2022022379A5 (ja)
JP2019081810A5 (ja)
JP2023085551A5 (ja)
JP2022060220A5 (ja)